银屑病治疗中生物制剂的临床效果与安全性评价  

Evaluation of Clinical Efficacy and Safety of Biologics in the Treatment of Psoriasis

作　　者：杜启 Qi Du(Pharmacy Department of Chongqing Traditional Chinese Medicine Hospital,Chongqing 400011)

机构地区：[1]重庆市中医院药剂科,重庆400011

出　　处：《医学研究前沿》2024年第5期55-57,共3页

摘　　要：目的本研究旨在评估生物制剂在银屑病治疗中的临床效果与安全性。方法选取了120例银屑病患者,随机分为生物制剂治疗组和对照组。治疗组接受生物制剂治疗,对照组接受传统治疗。治疗效果通过皮损面积和严重程度指数(PASI)评分评估,安全性通过不良反应发生率进行评估。结果生物制剂治疗组PASI评分显著降低,且不良反应发生率低于对照组。统计学分析显示,治疗组的临床效果优于对照组(P<0.05)。结论生物制剂在银屑病治疗中表现出显著的临床效果和较好的安全性,值得临床推广应用。Objective To evaluate the clinical efficacy and safety of biologics in the treatment of psoriasis.Methods We selected 120 pso⁃riasis patients,randomly divided into biological agents treatment group and control group.The treatment group was treated with biological agents,and the control group was treated with traditional therapy.Efficacy was assessed by the Skin Area and Severity Index(PASI)score,and safety was assessed by the incidence of adverse reactions.Results The score of PASI in the treatment group was significantly lower than that in the control group.The clinical effect of the treatment group was better than that of the control group(P<0.05).Conclusion Bio⁃logical agents in the treatment of psoriasis showed significant clinical efficacy and better safety,it is worthy of clinical application.

关 键 词：银屑病 生物制剂 临床效果 安全性 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]